Last reviewed · How we verify
Pneumococcal 20-valent conjugate vaccine (pneumococcal-20-valent-conjugate-vaccine)
Pneumococcal 20-valent conjugate vaccine (generic name: pneumococcal-20-valent-conjugate-vaccine) is a For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be Vaccine drug developed by Pfizer Inc.. It is currently in preclinical development.
For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be
The Pneumococcal 20-valent conjugate vaccine is a vaccine component that induces an immune response, classified as a biological vaccine. It is used to prevent pneumococcal infections, specifically those caused by Streptococcus pneumoniae, and is typically administered to adults aged 60 years and older.
-
Baseline preclinical → approval rate
+5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable. -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2036–2040 | — |
| EMA | EU | 2037–2041 | +0.7 yr |
| MHRA | GB | 2037–2041 | +0.7 yr |
| Health Canada | CA | 2037–2042 | +0.9 yr |
| TGA | AU | 2037–2042 | +1.2 yr |
| PMDA | JP | 2037–2042 | +1.5 yr |
| NMPA | CN | 2038–2043 | +2.3 yr |
| MFDS | KR | 2037–2042 | +1.4 yr |
| CDSCO | IN | 2037–2043 | +1.8 yr |
| ANVISA | BR | 2038–2043 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | pneumococcal-20-valent-conjugate-vaccine |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be |
| Modality | Vaccine |
| Therapeutic area | Immunology |
| Phase | preclinical |
Mechanism of action
Pneumococcal 20-valent conjugate vaccine works by introducing small pieces of 20 different pneumococcal bacteria strains into your body in a safe form. These bacterial components are attached to a carrier protein that acts like a signal flag, telling your immune system to pay attention. Your body then creates antibodies—specialized proteins—that can recognize these 20 pneumococcal types if you're ever exposed to the real bacteria. When you're later exposed to pneumococcal bacteria in real life, your pre-trained antibodies quickly identify and attack them before they can establish infection or spread through your bloodstream. This prevents both invasive infections (where bacteria enter the blood and organs) and pneumococcal pneumonia. The conjugate technology makes the vaccine particularly effective because it generates strong, lasting immune memory across different age groups. By covering 20 strains instead of fewer types, this vaccine protects against a larger proportion of the pneumococcal bacteria circulating in the population, reducing overall disease risk for vaccinated individuals.
Approved indications
Pipeline indications
- Pneumococcal Immunization — preclinical
Common side effects
Key clinical trials
- A Study to Learn About How a New Pneumococcal Vaccine Works in Adults (Phase 1)
- Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With (Phase 3)
- A Study to Learn About How a New Pneumococcal Vaccine Works in Children (Phase 2)
- Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 (Phase 3)
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (Phase 1)
- A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting (N/A)
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healt (Phase 3)
- Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal 20-valent conjugate vaccine CI brief — competitive landscape report
- Pneumococcal 20-valent conjugate vaccine updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Pneumococcal 20-valent conjugate vaccine
What is Pneumococcal 20-valent conjugate vaccine?
How does Pneumococcal 20-valent conjugate vaccine work?
Who makes Pneumococcal 20-valent conjugate vaccine?
What is the generic name of Pneumococcal 20-valent conjugate vaccine?
What drug class is Pneumococcal 20-valent conjugate vaccine in?
What development phase is Pneumococcal 20-valent conjugate vaccine in?
Related
- Drug class: All For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing